Clinical Trial Update: MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting results for MGC018 in relapsed or refractory extensive-stage small-cell lung cancer; the study is not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• MGC018

Snippet

Sponsor: Georgetown University | Conditions: Extensive-stage Small-cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-13